May 2009 Volume 27 Number 5, pp 397 - 486
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=48&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=1&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=143&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=4&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Direct PCR from Finnzymes
Would you like to forget about DNA purification prior to PCR?
With Finnzymes robust PCR enzymes you can amplify DNA directly
from materials such as blood, plants, mouse ear tissues, or FFPE samples.
Take the direct route from sample to results: Finnzymes Direct PCR.
http://links.ealert.nature.com/ctt?kn=106&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Phage Display & Cloning Competent Cells
http://links.ealert.nature.com/ctt?kn=56&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
TG1, ER2738, and SS320 (MC1061 F') cells. Lucigen is the only source
for the ultra-high efficiency electrocompetent cells (2-4 x 10^10 cfu/µg)
needed to make large phage display libraries. Custom dispensing and bulk
discounts available. Custom competent cells made from any strain.
Visit: http://links.ealert.nature.com/ctt?kn=120&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0 or email lucigen@lucigen.com
=====================================================================
=========================== ADVERTISEMENT ===========================
Play your part - Help bring new multiple sclerosis treatments to market.
$3 million in funding available now for innovative research and commercial
development proposals.
Who can apply?
- Academic investigators
- Seed and early stage companies
To submit your proposal visit: http://links.ealert.nature.com/ctt?kn=91&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Fast Forward(SM) Speeding treatments to people with MS
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://links.ealert.nature.com/ctt?kn=10&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Antibiotics and inhibition of fatty acid biosynthesis
http://links.ealert.nature.com/ctt?kn=174&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
The importance of fatty acid biosynthesis to bacterial survival has
made the pathway fertile ground for antibiotic targets, and at least
three companies are pursuing compounds that block the process. French
researchers, however, have challenged the approach with a paper in
Nature that describes how Gram-positive bacteria can assimilate host
fatty acids to ensure bacterial survival. What was the reaction of
companies developing inhibitors of the pathway?
Find out more by reading the first in-depth analysis of the scientific
and commercial potential of the work in SciBX: Science-Business
eXchange.
http://links.ealert.nature.com/ctt?kn=153&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Tuesday Think & Drink Discussion Forum
Hosted by the Editors of Nature Biotechnology at the BIO International Convention 2009
Georgia World Congress Center
Building A, Level 3, East Plaza Entrance
(Across from Sidney Marcus Auditorium Entrance)
Tuesday, May 19, 5:00 pm - 6:30 pm
Sponsored by: SUTHERLAND
Industry Is from Mars, Academia Is from Venus
More and more emphasis is being placed on cooperation between companies and academics to kick start translational research initiatives. But with the goals, culture, expertise and experience of researchers in industry and academia so different, numerous issues need to be addressed for such collaborations to run smoothly and be most productive.
Join us for a thought-provoking discussion and a tasty beverage during this fun and interactive networking opportunity.
=====================================================================
----------------------
EDITORIAL
----------------------
A strike against preemption p397
Industry has been warned: US Food and Drug Administration (FDA) approval is no shield against failure-to-warn or product-liability suits.
doi:10.1038/nbt0509-397
http://links.ealert.nature.com/ctt?kn=39&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
NEWS
----------------------
Wyeth preemption case ruling sparks labeling confusion pp399 - 400
Malorye Allison
doi:10.1038/nbt0509-399
http://links.ealert.nature.com/ctt?kn=25&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Health under DeParle and Sebelius p400
Emily Waltz
doi:10.1038/nbt0509-400a
http://links.ealert.nature.com/ctt?kn=46&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Google spawns venture fund p400
Victor Bethencourt
doi:10.1038/nbt0509-400b
http://links.ealert.nature.com/ctt?kn=49&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Cash infusion for HIV microbicides pp401 - 402
Nayanah Siva
doi:10.1038/nbt0509-401
http://links.ealert.nature.com/ctt?kn=177&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Corporate venture funds chase early-stage deals pp403 - 404
Peter Mitchell
doi:10.1038/nbt0509-403
http://links.ealert.nature.com/ctt?kn=181&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Mexico OKs GM corn p404
Veronica Guerrero
doi:10.1038/nbt0509-404
http://links.ealert.nature.com/ctt?kn=164&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Biotech fat cats p404
doi:10.1038/nbt0509-404b
http://links.ealert.nature.com/ctt?kn=167&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
FDA on warpath for Google links p405
Randy Osborne
doi:10.1038/nbt0509-405
http://links.ealert.nature.com/ctt?kn=69&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Healthcare reform looms, firms seek scraps from US stimulus pp406 - 408
Jeffrey L Fox
doi:10.1038/nbt0509-406
http://links.ealert.nature.com/ctt?kn=96&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Chugai reports Actemra deaths p407
Asher Mullard
doi:10.1038/nbt0509-407
http://links.ealert.nature.com/ctt?kn=121&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Irish biotech buoyant p408
Cormac Sheridan
doi:10.1038/nbt0509-408a
http://links.ealert.nature.com/ctt?kn=132&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Hospital to genotype all tumors p408
James Netterwald
doi:10.1038/nbt0509-408b
http://links.ealert.nature.com/ctt?kn=154&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
PROFILE
Richard Gold p409
Lawyer Richard Gold argues that superfluous patents stifle innovation. Industry should adopt new models, he says, in which knowledge is viewed as a club good.
Hannah Hoag
doi:10.1038/nbt0509-409
http://links.ealert.nature.com/ctt?kn=134&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
DATA PAGE
Biotech braves the winter in 1Q09 p410
Walter Yang
doi:10.1038/nbt0509-410
http://links.ealert.nature.com/ctt?kn=75&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
NEWS FEATURE
Academia and the company coin pp411 - 414
As the economic downturn chokes spin-outs from academia, a spate of newly minted university-industry partnerships are springing up. Failing to address the financial conflicts in such partnerships could spell trouble for both faculty and drug companies. Jim Kling investigates.
Jim Kling
doi:10.1038/nbt0509-411
http://links.ealert.nature.com/ctt?kn=144&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Translational Medicine Alliance Forum, May 13-15, 2009, Philadelphia, PA
Register now and join leading universities, disease foundations, corporations and investors as they discuss and develop more effective models to enable translational medicine. Register today at:
http://links.ealert.nature.com/ctt?kn=119&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Prepare to meet your partner
More and more collaborations are born from partnering meetings, but the size and hectic pace of these events can be overwhelming. To make the most of your time, go in prepared.
Cori Gorman, Cammie Edwards and Robert Meister
doi:10.1038/bioe.2009.3
http://links.ealert.nature.com/ctt?kn=60&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Regulating laboratory-developed tests p419
Hal Barron
doi:10.1038/nbt0509-419a
http://links.ealert.nature.com/ctt?kn=33&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Regulating laboratory-developed tests pp419 - 420
Kathy Hudson and Gail Javitt
doi:10.1038/nbt0509-419b
http://links.ealert.nature.com/ctt?kn=35&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Regulating laboratory-developed tests pp420 - 421
Alan Mertz
doi:10.1038/nbt0509-420
http://links.ealert.nature.com/ctt?kn=55&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Regulating laboratory-developed tests p421
Drew Fromkin
doi:10.1038/nbt0509-421
http://links.ealert.nature.com/ctt?kn=133&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
In need of a reality check p422
Steven Murphy
doi:10.1038/nbt0509-422
http://links.ealert.nature.com/ctt?kn=30&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
COMMENTARY
Gilead's deal of a lifetime p423
Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise.
Brady Huggett and Christopher Scott
doi:10.1038/nbt0509-423
http://links.ealert.nature.com/ctt?kn=40&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Proceeding in a receding economy pp424 - 425
The biotech sector must not only maintain an emphasis on ground-breaking products and focus on retaining key staff but also mobilize to ensure that US health policy continues to reward its innovations.
George A Scangos
doi:10.1038/nbt0509-424
http://links.ealert.nature.com/ctt?kn=8&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
BOOK REVIEW
Be reasonable p426
Derek Lowe reviews Reasonable Rx: Solving the Drug Price Crisis by Stan Finkelstein and Peter Temin
doi:10.1038/nbt0509-426
http://links.ealert.nature.com/ctt?kn=31&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
FEATURES
----------------------
Small but tenacious: South Africa's health biotech sector pp427 - 445
Despite a challenging business environment, entrepreneurial health biotech companies in South Africa are finding ways to succeed.
Sara Al-Bader et al.
doi:10.1038/nbt0509-427
http://links.ealert.nature.com/ctt?kn=5&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
PATENTS
Combine and conquer: handling biotech combination inventions in the wake of KSR pp446 - 448
To what extent will KSR limit combination inventions in biotech?
Ha Kung Wong and Dana Lau
doi:10.1038/nbt0509-446
http://links.ealert.nature.com/ctt?kn=210&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Recent patent applications in biological imaging p449
doi:10.1038/nbt0509-449
http://links.ealert.nature.com/ctt?kn=15&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Overpowering the component problem pp450 - 451
Synthetic gene networks can be readily redesigned using new libraries of quantitatively characterized promoters coupled with predictive mathematical modeling.
Matthew R Bennett and Jeff Hasty
doi:10.1038/nbt0509-450
http://links.ealert.nature.com/ctt?kn=163&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Expanded CAG repeats in the crosshairs pp451 - 452
Antisense oligomers targeted to CAG repeats allow allele-specific knockdown of the gene that causes Huntington's disease.
Neil Aronin
doi:10.1038/nbt0509-451
http://links.ealert.nature.com/ctt?kn=166&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Targeted instant immunity pp452 - 453
Antibodies can be programmed to bind cancer cells using covalently binding antigens and adapters.
Claude F Meares
doi:10.1038/nbt0509-452
http://links.ealert.nature.com/ctt?kn=193&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p454
doi:10.1038/nbt0509-454
http://links.ealert.nature.com/ctt?kn=61&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PRIMER
How to map billions of short reads onto genomes pp455 - 457
Mapping the vast quantities of short sequence fragments produced by next-generation sequencing platforms is a challenge. What programs are available and how do they work?
Cole Trapnell and Steven L Salzberg
doi:10.1038/nbt0509-455
http://links.ealert.nature.com/ctt?kn=117&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
BRIEF COMMUNICATIONS
Embryonic stem cell-specific microRNAs promote induced pluripotency pp459 - 461
Judson et al. show that microRNAs specific to mouse embryonic stem cells can substitute for the reprogramming factor cMyc in the generation of induced pluripotent stem cells. The development of reprogramming methods that do not rely on transgenes may facilitate clinical translation of this technology.
Robert L Judson, Joshua E Babiarz, Monica Venere and Robert Blelloch
doi:10.1038/nbt.1535
Abstract: http://links.ealert.nature.com/ctt?kn=130&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=150&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12 pp462 - 464
Hosaka et al. show that selection of bacteria for antibiotic resistance can be used to discover new antibacterials. Some of the mutant strains they generated, which bear mutations in RNA polymerase and in a ribosomal protein, produce a previously unknown class of antibacterial called piperidamycin.
Takeshi Hosaka et al.
doi:10.1038/nbt.1538
Abstract: http://links.ealert.nature.com/ctt?kn=73&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=80&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
ARTICLE
Diversity-based, model-guided construction of synthetic gene networks with predicted functions pp465 - 471
Ellis et al. describe a strategy for rationally assembling gene networks with predictable behaviors. Using mathematical models, they predict the responses of complex synthetic gene networks built from quantitatively characterized promoter libraries, and harness these networks to regulate an industrially relevant yeast phenotype.
Tom Ellis, Xiao Wang and James J Collins
doi:10.1038/nbt.1536
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=92&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
LETTERS
Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNA-directed repression pp472 - 477
Single-nucleotide polymorphisms in microRNA target sites can disrupt the effects of the microRNA. Kim and Bartel use sequencing to investigate this phenomenon on a large scale and find that such polymorphisms generate gene-regulatory diversity in mice.
Jinkuk Kim and David P Bartel
doi:10.1038/nbt.1540
Abstract: http://links.ealert.nature.com/ctt?kn=97&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=101&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs pp478 - 484
Strategies for allele-specific knockdown of the mutant genes in triplet-repeat disorders have relied on point or deletion mutations that differ among affected individuals. Hu et al. show that antisense oligomers can selectively recognize expanded CAG repeats in mRNAs, allowing silencing of mutant but not wild-type alleles.
Jiaxin Hu et al.
doi:10.1038/nbt.1539
Abstract: http://links.ealert.nature.com/ctt?kn=113&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=179&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
CORRIGENDA
Corrigendum: Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling p485
Stuart M Chambers et al.
doi:10.1038/nbt0509-485a
http://links.ealert.nature.com/ctt?kn=24&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Corrigendum: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells p485
Madeleine P Ball et al.
doi:10.1038/nbt0509-485b
http://links.ealert.nature.com/ctt?kn=38&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
ERRATA
Erratum: Biotech patents - business as usual? p485
Stacy Lawrence
doi:10.1038/nbt0509-485c
http://links.ealert.nature.com/ctt?kn=199&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Erratum: Proprietary science, open science and the role of patent disclosure: the case of zinc-finger proteins p485
Subhashini Chandrasekharan, Sapna Kumar, Cory M Valley and Arti Rai
doi:10.1038/nbt0509-485d
http://links.ealert.nature.com/ctt?kn=14&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Erratum: Biotech scientists bank on big pharma's biologics push p485
Grace Wong
doi:10.1038/nbt0509-485e
http://links.ealert.nature.com/ctt?kn=6&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
Erratum: Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes p485
Daniel A Bachovchin, Steven J Brown, Hugh Rosen and Benjamin F Cravatt
doi:10.1038/nbt0509-485f
http://links.ealert.nature.com/ctt?kn=211&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
PEOPLE
People p486
doi:10.1038/nbt0509-486
http://links.ealert.nature.com/ctt?kn=176&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Apply Now
2009 Nature Chemical Biology Symposium: Chemical Biology in Drug Discovery
Date: 19 - 20 September, 2009
Venue: Royal Sonesta Hotel, Cambridge, Massachusetts, USA
This 2009 symposium will explore how chemical biology is opening up new avenues for identifying therapeutic targets and discovering small molecule drugs.
Apply online now - priority application deadline is 22 May, 2009.
To apply to attend and to view the full 2-day program visit:
http://links.ealert.nature.com/ctt?kn=208&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=186&m=32908495&r=MTc3MTg2NzE2NgS2&b=2&j=NDk0MTA4MTgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
